每(mei)經(jing)AI快訊，天宇股份(fen)3月(yue)3日(ri)晚間公(gong)(gong)告(gao)(gao)，公(gong)(gong)司(si)(si)于(yu)2022年(nian)8月(yue)26日(ri)披露(lu)了關于(yu)美國食品藥品監督管理局(ju)（簡稱“FDA”）對公(gong)(gong)司(si)(si)黃巖江口生產場地(di)檢查出具警(jing)告(gao)(gao)信的公(gong)(gong)告(gao)(gao)。近日(ri)，公(gong)(gong)司(si)(si)收(shou)到(dao)FDA關于(yu)關閉警(jing)告(gao)(gao)信的通知函(han)，該通知函(han)告(gao)(gao)知：FDA已(yi)完成對公(gong)(gong)司(si)(si)2022年(nian)8月(yue)17日(ri)簽發的警(jing)告(gao)(gao)信所采取糾正措(cuo)施的評(ping)估。根據(ju)評(ping)估結果，FDA認為公(gong)(gong)司(si)(si)已(yi)有(you)效解決了該警(jing)告(gao)(gao)信中提及(ji)的偏差問(wen)題。本次FDA關閉公(gong)(gong)司(si)(si)黃巖江口生產場地(di)警(jing)告(gao)(gao)信，將(jiang)有(you)利(li)于(yu)公(gong)(gong)司(si)(si)產品市場的拓(tuo)展，同時對公(gong)(gong)司(si)(si)新產品的獲批將(jiang)起到(dao)積(ji)極的作用(yong)，有(you)助于(yu)提升公(gong)(gong)司(si)(si)的經(jing)營業績。